Editas Medicine, Inc. (EDIT)
NasdaqGS
Price as at 2 Oct 2026, 01:48 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Editas Medicine, Inc. trades at $2.52. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Editas Medicine, Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
8 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$8.00M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$6.60M · 0.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$6.16M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$5.09M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$4.32M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in EDIT
We hold 14 disclosed trades in EDIT by members of Congress and executive-branch officials. The latest 5:
- Daniel Goldman · HouseSell · $1,001 - $15,000 · traded 10 Apr 2023 · disclosed 19 May 2023
- Donald Sternoff Beyer Jr · HouseSell · $1,001 - $15,000 · traded 14 Apr 2021 · disclosed 1 May 2021
- Donald Sternoff Beyer Jr · HouseSell · $1,001 - $15,000 · traded 2 Mar 2021 · disclosed 1 Apr 2021
- Donald Sternoff Beyer Jr · HouseBuy · $1,001 - $15,000 · traded 17 Nov 2020 · disclosed 1 Dec 2020
- Donald Sternoff Beyer Jr · HouseSell · $1,001 - $15,000 · traded 1 May 2020 · disclosed 31 May 2020
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
Common questions
Which funds own EDIT?
8 of the institutions we track reported a position in EDIT in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its EDIT data?
Fundamentals for EDIT come from company filings and exchange data, as listed on NasdaqGS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 2 Oct 2026, 01:48 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for EDIT, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.